{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T12:38:10Z","timestamp":1795005490326,"version":"4.9.1"},"reference-count":61,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,3,2]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Increased immune suppressors and PD-1 abrogates effector responses in CML patients at diagnosis. Enhanced net effector immune responses and decreased PD-1 and immune suppressors may promote sustained deep molecular response in CML.<\/jats:p>","DOI":"10.1182\/blood-2016-10-745992","type":"journal-article","created":{"date-parts":[[2017,1,4]],"date-time":"2017-01-04T02:00:28Z","timestamp":1483495228000},"page":"1166-1176","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":177,"title":["CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors"],"prefix":"10.1182","volume":"129","author":[{"given":"Amy","family":"Hughes","sequence":"first","affiliation":[{"name":"Department of Haematology, SA Pathology, Adelaide, SA, Australia;"},{"name":"Cancer Theme, South Australia Health and Medical Research Institute, Adelaide, SA, Australia; and"},{"name":"School of Medicine, The University of Adelaide, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Clarson","sequence":"additional","affiliation":[{"name":"Department of Haematology, SA Pathology, Adelaide, SA, Australia;"},{"name":"Cancer Theme, South Australia Health and Medical Research Institute, Adelaide, SA, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Haematology, SA Pathology, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ljiljana","family":"Vidovic","sequence":"additional","affiliation":[{"name":"Department of Haematology, SA Pathology, Adelaide, SA, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah L.","family":"White","sequence":"additional","affiliation":[{"name":"Cancer Theme, South Australia Health and Medical Research Institute, Adelaide, SA, Australia; and"},{"name":"School of Medicine, The University of Adelaide, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Haematology, SA Pathology, Adelaide, SA, Australia;"},{"name":"Cancer Theme, South Australia Health and Medical Research Institute, Adelaide, SA, Australia; and"},{"name":"School of Medicine, The University of Adelaide, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes S. M.","family":"Yong","sequence":"additional","affiliation":[{"name":"Department of Haematology, SA Pathology, Adelaide, SA, Australia;"},{"name":"Cancer Theme, South Australia Health and Medical Research Institute, Adelaide, SA, Australia; and"},{"name":"School of Medicine, The University of Adelaide, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2019111904114333800_B1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1078-0432.CCR-13-1988","article-title":"Deep molecular response in chronic myeloid leukemia: the new goal of therapy?","volume":"20","author":"Mahon","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019111904114333800_B2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019111904114333800_B3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1600-0609.2010.01501.x","article-title":"Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy","volume":"85","author":"Rohon","year":"2010","journal-title":"Eur J Haematol"},{"key":"2019111904114333800_B4","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/137320","article-title":"Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment","volume-title":"Clin Dev Immunol","author":"Humlova","year":"2010"},{"issue":"3","key":"2019111904114333800_B5","first-page":"17","article-title":"Immunomodulatory effects of tyrosine kinase inhibitors","volume":"1","author":"Kreutzman","year":"2013","journal-title":"Int Trends Immun"},{"issue":"2","key":"2019111904114333800_B6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/imm.12036","article-title":"The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells","volume":"138","author":"Lindau","year":"2013","journal-title":"Immunology"},{"issue":"5","key":"2019111904114333800_B7","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/blood.V96.5.1961","article-title":"Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine","volume":"96","author":"Mellqvist","year":"2000","journal-title":"Blood"},{"issue":"3","key":"2019111904114333800_B8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/leu.2011.239","article-title":"NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice","volume":"26","author":"Chen","year":"2012","journal-title":"Leukemia"},{"issue":"21","key":"2019111904114333800_B9","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood.V124.21.812.812","article-title":"Early disease relapse after tyrosine kinase inhibitor treatment discontinuation in CML is related both to low number and impaired function of NK-cells [abstract]","volume":"124","author":"Ilander","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2019111904114333800_B10","first-page":"856","article-title":"Low natural killer (NK) cell counts and functionality are associated with molecular relapse after imatinib discontinuation in patients (pts) with chronic phase (CP)-chronic myeloid leukemia (CML) with undetectable BCR-ABL transcripts for at least 2 years: preliminary results from immunostim, on behalf of STIM Investigators [abstract]","volume":"122","author":"Rea","year":"2013","journal-title":"Blood"},{"key":"2019111904114333800_B11","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1038\/bcj.2014.50","article-title":"The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity","volume":"4","author":"Ahmad","year":"2014","journal-title":"Blood Cancer J"},{"issue":"9","key":"2019111904114333800_B12","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/cncr.29933","article-title":"Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity","volume":"122","author":"Schiffer","year":"2016","journal-title":"Cancer"},{"issue":"12","key":"2019111904114333800_B13","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1182\/blood-2012-07-440099","article-title":"Lineage relationships of human interleukin-22-producing CD56+ ROR\u03b3t+ innate lymphoid cells and conventional natural killer cells","volume":"121","author":"Ahn","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2019111904114333800_B14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/leu.2010.325","article-title":"Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein","volume":"25","author":"Yong","year":"2011","journal-title":"Leukemia"},{"issue":"10","key":"2019111904114333800_B15","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/blood-2008-03-144071","article-title":"Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia","volume":"113","author":"Rezvani","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2019111904114333800_B16","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/leu.2009.70","article-title":"WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation","volume":"23","author":"Weber","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"2019111904114333800_B17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2012-11-465039","article-title":"Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling","volume":"122","author":"de Lavallade","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2019111904114333800_B18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1586\/1744666X.2015.1019474","article-title":"Immunology of chronic myeloid leukemia: current concepts and future goals","volume":"11","author":"Vonka","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"issue":"10","key":"2019111904114333800_B19","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"issue":"26","key":"2019111904114333800_B20","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111904114333800_B21","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2019111904114333800_B22","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/leu.2016.121","article-title":"Safety and efficacy of the combination of pegylated interferon-\u03b12b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients","volume":"30","author":"Hjorth-Hansen","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"2019111904114333800_B23","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/sj.leu.2402988","article-title":"WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies","volume":"17","author":"Rosenfeld","year":"2003","journal-title":"Leukemia"},{"issue":"2","key":"2019111904114333800_B24","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1182\/blood-2007-02-071738","article-title":"High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects","volume":"110","author":"Yong","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2019111904114333800_B25","doi-asserted-by":"crossref","first-page":"e11770","DOI":"10.1371\/journal.pone.0011770","article-title":"PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal","volume":"5","author":"Kanodia","year":"2010","journal-title":"PLoS One"},{"issue":"2","key":"2019111904114333800_B26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/onc.2010.409","article-title":"BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients","volume":"30","author":"De Carvalho","year":"2011","journal-title":"Oncogene"},{"issue":"12","key":"2019111904114333800_B27","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1182\/blood-2010-08-300376","article-title":"High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells","volume":"117","author":"Quintarelli","year":"2011","journal-title":"Blood"},{"issue":"6937","key":"2019111904114333800_B28","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nature01587","article-title":"Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells","volume":"423","author":"Park","year":"2003","journal-title":"Nature"},{"issue":"10","key":"2019111904114333800_B29","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1038\/leu.2015.112","article-title":"The BMI1 polycomb protein represses cyclin G2-induced autophagy to support proliferation in chronic myeloid leukemia cells","volume":"29","author":"Mourgues","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"2019111904114333800_B30","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2007-08-108241","article-title":"Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies","volume":"111","author":"Rezvani","year":"2008","journal-title":"Blood"},{"issue":"26","key":"2019111904114333800_B31","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1182\/blood-2009-02-202598","article-title":"A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS","volume":"113","author":"Keilholz","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2019111904114333800_B32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood-2009-10-250993","article-title":"Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia","volume":"116","author":"Maslak","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111904114333800_B33","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00262-011-1126-z","article-title":"Antigens in chronic myeloid leukemia: implications for vaccine development","volume":"60","author":"Smahel","year":"2011","journal-title":"Cancer Immunol Immunother"},{"issue":"21","key":"2019111904114333800_B34","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1182\/blood-2014-01-549022","article-title":"A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias","volume":"123","author":"Dubrovsky","year":"2014","journal-title":"Blood"},{"issue":"16","key":"2019111904114333800_B35","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1182\/blood-2010-07-299248","article-title":"An anti-PR1\/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells","volume":"117","author":"Sergeeva","year":"2011","journal-title":"Blood"},{"issue":"176","key":"2019111904114333800_B36","doi-asserted-by":"crossref","first-page":"176ra33","DOI":"10.1126\/scitranslmed.3005661","article-title":"Targeting the intracellular WT1 oncogene product with a therapeutic human antibody","volume":"5","author":"Dao","year":"2013","journal-title":"Sci Transl Med"},{"issue":"2","key":"2019111904114333800_B37","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1128\/JVI.01675-09","article-title":"HIV infection is associated with a preferential decline in less-differentiated CD56dim CD16+ NK cells","volume":"84","author":"Hong","year":"2010","journal-title":"J Virol"},{"issue":"10","key":"2019111904114333800_B38","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1182\/blood.V99.10.3661","article-title":"Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia","volume":"99","author":"Costello","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2019111904114333800_B39","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood-2005-08-027979","article-title":"Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction","volume":"109","author":"Fauriat","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2019111904114333800_B40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2567.2011.03521.x","article-title":"Expression of natural killer cell activating receptors in patients with chronic lymphocytic leukaemia","volume":"135","author":"Costello","year":"2012","journal-title":"Immunology"},{"issue":"8","key":"2019111904114333800_B41","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.4049\/jimmunol.176.8.5108","article-title":"BCR\/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia","volume":"176","author":"Boissel","year":"2006","journal-title":"J Immunol"},{"issue":"6","key":"2019111904114333800_B42","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/ijc.29889","article-title":"Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: a mixed-treatment comparison","volume":"138","author":"Firwana","year":"2016","journal-title":"Int J Cancer"},{"issue":"8","key":"2019111904114333800_B43","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The concept of treatment-free remission in chronic myeloid leukemia","volume":"30","author":"Sau\u00dfele","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"2019111904114333800_B44","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrclinonc.2016.41","article-title":"Immunological off-target effects of imatinib","volume":"13","author":"Zitvogel","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"2019111904114333800_B45","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fonc.2015.00107","article-title":"Myeloid derived suppressor cells in chronic myeloid leukemia","volume":"5","author":"Giallongo","year":"2015","journal-title":"Front Oncol"},{"issue":"6","key":"2019111904114333800_B46","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-08-1332","article-title":"Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients","volume":"15","author":"Ko","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019111904114333800_B47","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2019111904114333800_B48","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.4049\/jimmunol.1200602","article-title":"Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome","volume":"189","author":"Mailloux","year":"2012","journal-title":"J Immunol"},{"issue":"9","key":"2019111904114333800_B49","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ajh.24096","article-title":"Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study","volume":"90","author":"Iriyama","year":"2015","journal-title":"Am J Hematol"},{"issue":"9","key":"2019111904114333800_B50","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"issue":"9","key":"2019111904114333800_B51","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","article-title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib","volume":"123","author":"Hughes","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111904114333800_B52","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"issue":"19","key":"2019111904114333800_B53","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111904114333800_B54","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2002-02-0659","article-title":"Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia","volume":"101","author":"Burchert","year":"2003","journal-title":"Blood"},{"issue":"8","key":"2019111904114333800_B55","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1182\/blood-2003-01-0150","article-title":"Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation","volume":"102","author":"Rezvani","year":"2003","journal-title":"Blood"},{"issue":"23","key":"2019111904114333800_B56","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1182\/blood.V126.23.4033.4033","article-title":"Increased TACE (tumor necrosis factor-alpha\u00b1-converting enzyme; ADam17) activity associates with decreased cd62l expression, increased soluble cd62l plasma levels and predicts molecular response to nilotinib therapy in patients with early chronic phase chronic myelogenous leukemia (CML-CP): results from an ENEST1st substudy [abstract]","volume":"126","author":"Sopper","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2019111904114333800_B57","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"issue":"1","key":"2019111904114333800_B58","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4049\/jimmunol.182.1.240","article-title":"Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1","volume":"182","author":"Li","year":"2009","journal-title":"J Immunol"},{"issue":"6-7","key":"2019111904114333800_B59","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3109\/08820139.2012.678023","article-title":"Highlights on molecular mechanisms of MDSC-mediated immune suppression: paving the way for new working hypotheses","volume":"41","author":"Solito","year":"2012","journal-title":"Immunol Invest"},{"key":"2019111904114333800_B60","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"issue":"3","key":"2019111904114333800_B61","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/cmi.2013.2","article-title":"Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy","volume":"10","author":"Pedroza-Pacheco","year":"2013","journal-title":"Cell Mol Immunol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/9\/1166\/1402642\/blood745992.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/9\/1166\/1402642\/blood745992.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T09:14:48Z","timestamp":1574154888000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/9\/1166\/36566\/CML-patients-with-deep-molecular-responses-to-TKI"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,2]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,3,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-10-745992","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,2]]}}}